|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,774.00 GBX | -0.50% |
|
-1.98% | +32.42% |
| 02:29am | GSK Wins US FDA's Orphan Drug Designation for Small-cell Lung Cancer Treatment | MT |
| 02:25am | GSK announces GSK'227 US FDA Orphan Drug Designation in SCLC | RE |
Published on 09/29/2025 at 11:21 am EDT
Bloomberg videos, provided by MT Newswires
Emma N.
Walmsley currently works at GSK Plc, as Chief Executive Officer & Executive Director from 2017, GlaxoSmithKline Australia Pty Ltd., as Chief Executive Officer, GlaxoSmithKline Korea Ltd., as Group President & Chief Executive Officer, Microsoft Corp., as Independent Director from 2019, and Stanford Medicine, as Member.
Ms. Walmsley also formerly worked at GlaxoSmithKline Consumer Healthcare Pte Ltd., as Chief Executive Officer, Haleon UK Holdings Ltd., as Chief Executive Officer, Diageo Plc, as Non-Executive Director in 2016, Haleon UK Holdings (No.2) Ltd., as Director from 2019 to 2022, L'Oreal (China) Co., Ltd., as General Manager-Consumer Products, and Maybelline LLC, as Global Brand Head from 2002 to 2007.
Ms. Walmsley received her graduate degree from the University of Oxford.
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Select your edition
All financial news and data tailored to specific country editions
